Publications

Case Reports Epublish 3 citations
Electronic publication date
April 11, 2024

View on Pubmed.gov 38601755 | View on doi.org 10.3389/fonc.20...

Case report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiota.

Search for publications in this journal Front Oncol

Abstract

Locally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses with chemotherapy. The increasingly significant use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) in different breast cancer settings has led to clinical trials focusing on this strategy as a primary treatment, with promising results. The impact of the microbiota on cancer, and vice-versa, is an emerging topic in oncology. The authors report a clinical case of a postmenopausal female patient with an invasive breast carcinoma of the right breast, Luminal B-like, staged as cT4cN3M0 (IIIB). Since the lesion was considered primarily inoperable, the patient started letrozole and ribociclib. Following 6 months of systemic therapy, the clinical response was significant, and surgery with curative intent was performed. The final staging was ypT3ypN2aM0, R1, and the patient started adjuvant letrozole and radiotherapy. This case provides important insights on primary CDK4/6i plus ET in locally advanced unresectable HR+/HER2- breast cancer and its potential implications in disease management further ahead. The patient's gut microbiota was analyzed throughout the disease course and therapeutic approach, evidencing a shift in gut microbial dominance from Firmicutes to Bacteroidetes and a loss of microbial diversity following 6 months of systemic therapy. The analysis of the intratumoral microbiota from the surgical specimen revealed high microbial dissimilarity between the residual tumor and respective margins.

References

PLoS One. 2016 Jan 05;11(1):e0146509

BMC Microbiol. 2022 Feb 12;22(1):53

Front Microbiol. 2021 Feb 25;12:584332

J Clin Med. 2023 Mar 13;12(6):

Cited by 3 citations (total)

Journal Article Review

Intratumoral Microbiota: Insights from Anatomical, Molecular, and Clinical Perspectives.

Electronic publication date November 26, 2024

Search for publications in this journal J Pers Med

Claudia Lombardo [...] Carla Agata Erika Loreto et al.

The human microbiota represents a heterogeneous microbial community composed of several commensal, symbiotic, and even pathogenic microorganisms colonizing both the...

Journal Article

Endoscopic surgery affects the gut microbiota and its metabolism in breast cancer patients.

Electronic publication date January 22, 2025

Search for publications in this journal Front Microbiol

Jingtai Li [...] Guankui Du et al.

Background

Despite the advantages of endoscopic surgery in reducing trauma and enhancing recovery for breast cancer patients, its impact on gut...

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

MeSH

Specialties

Copyright

Copyright © 2024 Vilhais, Alpuim Costa, Fontes-Sousa, Ribeiro, Martinho, Botelho de Sousa, Santos, Negreiros, Canastra, Borralho, Guia Pereira, Marçal, Germano Sousa, Chaleira, Rocha, Calhau and Faria.